Indications and uses
According to homeopathic principles these drops are indicated for Women with acute or chronic dry eyes, often associated with hormone imbalance, Sjogren's or excessive watering secondary to dry eye.
According to homeopathic principles these drops are indicated for Women with acute or chronic dry eyes, often associated with hormone imbalance, Sjogren's or excessive watering secondary to dry eye.
Instill one or two drops in the affected eye(s) as needed.
- Store at room temperature. - Discard 30 days after opening.
| Pulsatilla | 8x | Indicated for dry eye associated with hormonal fluctuation, both on a monthly basis or with menopause. |
| Sepia | 8x | Indicated for dryness which develops after menopause or hormonal imbalance. |
| Euphrasia (Eyebright) | 5x | Eyebright is often referred to as a "tonic for the eyes" and is indicated for inflammation of the conjunctiva, cornea and lids, including meibomian glands. Symptoms include redness, dryness, lachrymation and burning of the lid margin. |
| Alumina | 10x | Indicated for dryness of the eyes and other mucous membranes due to lack of aqueous secretion, "Sjogren's Syndrome". |
| Arsenicum album | 12x | Indicated for severe dryness due to inflammation and ulceration. |
| Nux mosch | 6x | Nux m. is the main remedy indicated for severe aqueous deficiency such as with Sjogren's Syndrome. |
| Zincum met | 10x | Indicated for extreme dryness, inflammation and burning. |
| Pulsatilla | 8x |
| Sepia | 8x |
| Euphrasia (Eyebright) | 5x |
| Alumina | 10x |
| Arsenicum album | 12x |
| Nux mosch | 6x |
| Zincum m | 10x |
| Sterile water (non-preserved) |
| Polysorbate 80 |
| Citrates |
| Sodium chloride |
According to homeopathic principles these drops are indicated for Women with acute or chronic dry eyes, often associated with hormone imbalance, Sjogren's or excessive watering secondary to dry eye.
Instill one or two drops in the affected eye(s) as needed.
- For ophthalmic use only.
- If you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours, discontinue use and consult a doctor.
- For Professional Use Only
Keep out of reach of children.
- Store at room temperature.
- Discard 30 days after opening.
Natural Ophthalmics, Inc
Dillon, CO, 80435
1-877-220-9710
www.natoph.com
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 68770-101-15 | 2025-12-23 | C162847 | 48780-1 | 97449f38-cfc2-f6ea-e053-dbdaa90aa703 | Women's Dry Eye |
| 68770-101-15 | 2022-01-28 | C162847 | 48780-1 | 97449f38-cfc2-f6ea-e053-dbdaa90aa703 | Women's Dry Eye |
| 68770-101-15 | 2019-12-20 | C162847 | 48780-1 | 97449f38-cfc2-f6ea-e053-dbdaa90aa703 | Women's Dry Eye |
| 68770-101-15 | 2019-11-13 | C162847 | 48780-1 | 97449f38-cfc2-f6ea-e053-dbdaa90aa703 | Women's Dry Eye |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Aluminum Oxide | ACTIVE INGREDIENT | LMI26O6933 | 1 | |
| Arsenic Trioxide | ACTIVE INGREDIENT | S7V92P67HO | 1 | |
| Euphrasia Stricta | ACTIVE INGREDIENT | C9642I91WL | 1 | |
| Nutmeg | ACTIVE INGREDIENT | AEE24M3MQ9 | 1 | |
| Pulsatilla Vulgaris | ACTIVE INGREDIENT | I76KB35JEV | 1 | |
| Sepia Officinalis Juice | ACTIVE INGREDIENT | QDL83WN8C2 | 1 | |
| Zinc | ACTIVE INGREDIENT | J41CSQ7QDS | 1 | |
| Aluminum Oxide | ACTIVE MOIETY | LMI26O6933 | 1 | |
| Arsenic Trioxide | ACTIVE MOIETY | S7V92P67HO | 1 | |
| Euphrasia Stricta | ACTIVE MOIETY | C9642I91WL | 1 | |
| Nutmeg | ACTIVE MOIETY | AEE24M3MQ9 | 1 | |
| Pulsatilla Vulgaris | ACTIVE MOIETY | I76KB35JEV | 1 | |
| Sepia Officinalis Juice | ACTIVE MOIETY | QDL83WN8C2 | 1 | |
| Zinc | ACTIVE MOIETY | J41CSQ7QDS | 1 | |
| Citric Acid Monohydrate | INACTIVE INGREDIENT | 2968PHW8QP | 1 | |
| Polysorbate 80 | INACTIVE INGREDIENT | 6OZP39ZG8H | 1 | |
| Sodium Chloride | INACTIVE INGREDIENT | 451W47IQ8X | 1 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 68770-101 | 68770-101-15 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| WATER | 059QF0KO0R | IACT |
| POLYSORBATE 80 | 6OZP39ZG8H | IACT |
| CITRIC ACID MONOHYDRATE | 2968PHW8QP | IACT |
| SODIUM CHLORIDE | 451W47IQ8X | IACT |
| PULSATILLA VULGARIS | I76KB35JEV | ACTIB |
| SEPIA OFFICINALIS JUICE | QDL83WN8C2 | ACTIB |
| EUPHRASIA STRICTA | C9642I91WL | ACTIB |
| ALUMINUM OXIDE | LMI26O6933 | ACTIB |
| ARSENIC TRIOXIDE | S7V92P67HO | ACTIB |
| NUTMEG | AEE24M3MQ9 | ACTIB |
| ZINC | J41CSQ7QDS | ACTIB |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | CAPSULE, COATED / ORAL | 0.04 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION / OPHTHALMIC | 1 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 900 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUPPOSITORY / VAGINAL | 28 mg | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | POWDER, DENTIFRICE / DENTAL | 0.03 mg/mg | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRA-ARTICULAR | 26 mg | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INFILTRATION | 3535 mg | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TROCHE / ORAL | 12 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SOLUTION/ DROPS / OPHTHALMIC | 0.25 %w/v | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | POWDER, FOR SOLUTION / OPHTHALMIC | 0.9 %w/w | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / INTRAMUSCULAR | 17 mg | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / INTRA-ARTICULAR | ADJ PH | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION, CONCENTRATE / IRRIGATION | 1 mg | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / INTRAVENOUS | 396 mg | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION / RESPIRATORY (INHALATION) | 0.03 %w/v | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / INTRAVENOUS | 10 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | POWDER / ORAL | 66 mg | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, EXTENDED RELEASE / ORAL | 45 mg | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / OPHTHALMIC | 13 mg | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 0.68 %w/v | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | GEL / TOPICAL | 1 mg | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION / INTRALESIONAL | 13 mg | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRALESIONAL | ADJ PH | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRALESIONAL | 0.9 %w/v | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / SOFT TISSUE | ADJ PH | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, EMULSION / INTRAVENOUS | 0.62 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SOLUTION/ DROPS / AURICULAR (OTIC) | 13 mg | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / OPHTHALMIC | 10 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | TABLET, ORALLY DISINTEGRATING / ORAL | 1 mg | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRADERMAL | 7 mg | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SYRUP / ORAL | 722 mg/5ml | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SUSPENSION / INTRASYNOVIAL | 4 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SOLUTION / RECTAL | 315 mg | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, EFFERVESCENT / ORAL | 460 mg | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | DROPS / NASAL | NA | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | DROPS / OPHTHALMIC | 0.08 %w/w | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / INTRAMUSCULAR | 9 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION / RESPIRATORY (INHALATION) | 1 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | TABLET, DELAYED RELEASE / ORAL | 4 mg | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRATHECAL | 1.35 mg | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | CREAM / TOPICAL | 0.4 %w/w | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | LIQUID / RESPIRATORY (INHALATION) | 0.13 %w/w | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER, FOR SUSPENSION / ORAL | 840 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | TABLET, FILM COATED / ORAL | 24 mg | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | TABLET, FILM COATED / ORAL | 100 mg | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRAMUSCULAR | 1486 mg | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRABURSAL | 9 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION / INTRAVENOUS | 4680 mg | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / ENDOTRACHEAL | 7.6 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SUSPENSION / INTRAVITREAL | 0.02 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | CAPSULE, LIQUID FILLED / ORAL | 24 mg | ||
| Citric Acid Monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | CAPSULE / ORAL | 238 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR | 1 mg | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | JELLY / NASAL | NA | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SUSPENSION / INTRA-ARTICULAR | 45 mg | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | LOTION / TOPICAL | 0.3 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION / INTRAMUSCULAR | 4 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SUSPENSION / INTRAVENOUS | 0.5 %w/v | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION, CONCENTRATE / SUBCUTANEOUS | 0.86 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION / AURICULAR (OTIC) | 1 %w/v |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 46aa0b61-fedd-9b70-e063-6394a90a87eb | 2adc2c1e-0ef4-4d52-979f-b37096cef55a | 2025-12-23 | Warnings | 2adc2c1e-0ef4-4d52-979f-b37096cef55a |
Adverse event summaries are temporarily unavailable. Other product information remains available.